4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a […]
Over the past several years as microbiome drug development programs continued to advance worldwide, the entire industry looked to the most clinically advanced companies to see whether their Phase 2 and 3 clinical trials would […]
There is no excerpt because this is a protected post.
Abstract Year 2020 has been a pivotal year for microbiome-focused drug companies. This year the industry saw the release of two much-anticipated Phase 3 studies, which showed positive results and set the stage for new […]
Anyone who has experienced “butterflies in the stomach” before giving a big presentation will be unsurprised to learn there is a physical connection between their gut and their brain. Neuroscientists and medical professionals call this […]
Viruses are ubiquitous structures that can infect cells from various forms of life. Determining viral community structure and function in association with health and disease is of increasing interest. This field, also known as viral […]
Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, […]
MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it was awarded 2.0 million Euros ($2.3 million) by the European Union as part of its Horizon 2020 Program. The grant will support the development of a […]
A new study published this week in the journal Philosophical Transactions of the Royal Society B demonstrates a first attempt at using the methods of ancient bacterial detection, pioneered in studies of past epidemics, to […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. […]
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. […]